IOVA — Iovance Biotherapeutics Income Statement
0.000.00%
Last trade - 00:00- $1.41bn
- $1.12bn
- $263.50m
Annual income statement for Iovance Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 1.19 | 164 | 264 |
| Cost of Revenue | |||||
| Gross Profit | — | — | -9.57 | 40.1 | 90.3 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 343 | 399 | 462 | 559 | 667 |
| Operating Profit | -343 | -399 | -461 | -395 | -403 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -342 | -396 | -448 | -375 | -393 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -342 | -396 | -444 | -372 | -391 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -342 | -396 | -444 | -372 | -391 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -342 | -396 | -444 | -372 | -391 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.23 | -2.49 | -1.89 | -1.27 | -1.08 |